Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of agents recently introduced in the clinic for the treatment of advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) BC. Palbociclib, ribociclib and abemaciclib have all been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency among other regulatory bodies
Hormone-receptor-positive Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Metastatic Breast Cancer
DRUG: Palbociclib
1-year Progression free survival (PFS), the time from enrollment until first evidence of disease progression or death, 1 year
Neutropenia, Grade 3 or 4 neutropenia, 1 year
Several factors are thought to influence the variability of treatment efficacy and toxicity, including organ function, comedications, hormonal status, body weight, age, comorbidities, etc. Among them, single nucleotide polymorphisms (SNPs) as rs1128503, rs2032583 are attracting huge interest to address the interindividual variability in drug response, whether in terms of efficacy or safety